Chemoenzymatic site-selective attachment to antibodies: using glycosylation sites to post-translationally program function

Chemoenzymatic site-selective attachment to antibodies: using glycosylation sites to post-translationally program function

Dades bibliogràfiques
Autor principal:	Khan, MA
Altres autors:	Davis, B
Format:	Thesis
Idioma:	English
Publicat:	2021
Matèries:	Chemical biology Antibody Glycobiology Chemistry Bispecific antibodies

Ítems similars

The antibody-binding Fc gamma receptor IIIa / CD16a is N-glycosylated with high occupancy at all five sites
per: Elizabeth A. Lampros, et al.
Publicat: (2022-01-01)

Investigations into novel enzymatic glycosylation methods
per: Taylor, T
Publicat: (2015)

Bispecific antibodies: design, therapy, perspectives
per: Sedykh SE, et al.
Publicat: (2018-01-01)

Investigating the N-linked glycan specificity of bacterial endo-beta-N-acetylglucosaminidase S
per: Goodfellow, J, et al.
Publicat: (2011)

Labeling glycans on living cells by a chemoenzymatic glycoengineering approach
per: Ruben T. Almaraz, et al.
Publicat: (2017-06-01)

Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
per: Suheil Albert Atallah-Yunes, et al.
Publicat: (2022-01-01)

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
per: Gihoon You, et al.
Publicat: (2021-07-01)

Role of antibody-based therapy in indolent non-Hodgkin's lymphoma
per: Patrick Willard, et al.
Publicat: (2021-01-01)

Bispecific antibody drug conjugates: Making 1+1>2
per: Yilin Gu, et al.
Publicat: (2024-05-01)

Targeting Herpes Simplex Virus Glycoprotein D with Bispecific Antibodies: Expanding Therapeutic Horizons by Searching for Synergy
per: Doina Atanasiu, et al.
Publicat: (2025-02-01)

Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
per: Masaud Shah, et al.
Publicat: (2025-01-01)

Cancer-specific glycosylation of CD13 impacts its detection and activity in preclinical cancer tissues
per: Francis M. Barnieh, et al.
Publicat: (2023-11-01)

Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
per: Pan H, et al.
Publicat: (2018-05-01)

Incorporation of trehalose analogues into Mycobacterium Tuberculosis: antigen 85 and probes of bacterial infection
per: Backus, K
Publicat: (2011)

Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase
per: Kevin E. Ramos, et al.
Publicat: (2024-07-01)

Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth
per: Ku, Zhiqiang, et al.
Publicat: (2023)

Construction of Novel Bispecific Single-Domain Antibodies (BiSdAbs) with Potent Antiangiogenic Activities
per: Xianglei Liu, et al.
Publicat: (2020-03-01)

Modified Therapeutic Antibodies: Improving Efficacy
per: Ji-Min Dai, et al.
Publicat: (2021-11-01)

Inhibitory superagonistic antibodies as novel therapeutics
per: Donat, RF
Publicat: (2023)

Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows
per: Caitlin Fawcett, et al.
Publicat: (2024-12-01)

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
per: Waqqas Tai, et al.
Publicat: (2022-03-01)

Corrigendum: Comparing Antibody Interfaces to Inform Rational Design of New Antibody Formats
per: Monica L. Fernández-Quintero, et al.
Publicat: (2022-02-01)

Bispecific antibodies: a novel approach for targeting prominent biomarkers
per: Akshita Gupta, et al.
Publicat: (2020-11-01)

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
per: Gabriele Antonarelli, et al.
Publicat: (2021-08-01)

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
per: Emilia Rabia, et al.
Publicat: (2023-04-01)

Bispecific antibodies for viral immunotherapy
per: Elisabeth K. Nyakatura, et al.
Publicat: (2017-04-01)

Antigenic and immunomodulatory properties of HIV-1 gp120 N-linked glycosylation
per: Bonomelli, C
Publicat: (2013)

One N-glycan regulates natural killer cell antibody-dependent cell-mediated cytotoxicity and modulates Fc γ receptor IIIa/CD16a structure
per: Paul G Kremer, et al.
Publicat: (2024-10-01)

Emerging Antibodies in Cancer Therapy
per: Yaping Sun, et al.
Publicat: (2023-01-01)

Editorial: Therapeutic antibody domains against cancer
per: Qi Zhao, et al.
Publicat: (2023-08-01)

Design, synthesis and biological evaluation of glycosidase inhibitors in an anti-cancer setting
per: Glawar, AFG
Publicat: (2013)

Producing and prospects for the use of bispecific antibodies for the treatment of cancer
per: S. E. Sedykh, et al.
Publicat: (2019-01-01)

Intein mediated high throughput screening for bispecific antibodies
per: Tim Hofmann, et al.
Publicat: (2020-01-01)

Injection site reaction to teclistamab in a patient with multiple myeloma
per: Isabel C. Yoon, BS, et al.
Publicat: (2025-02-01)

Editorial: Endo- and transcytotic pathways at the brain barriers
per: Michelle A. Erickson, et al.
Publicat: (2024-05-01)

The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use
per: Rita Tavarozzi, et al.
Publicat: (2022-02-01)

Engineering multi-specific antibodies against HIV-1
per: Neal N. Padte, et al.
Publicat: (2018-08-01)

Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1
per: Junpeng Qi, et al.
Publicat: (2019-08-01)

Developability considerations for bispecific and multispecific antibodies
per: Alaa Amash, et al.
Publicat: (2024-12-01)

Rapid Generation of Murine Bispecific Antibodies Using FAST-Ig<sup>TM</sup> for Preclinical Screening of HER2/CD3 T-Cell Engagers
per: Hikaru Koga, et al.
Publicat: (2024-01-01)